Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Device Approval”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,675 records · Page 93Linked to original sources

In vivo survival of apheresis RBCs, frozen with 40-percent (wt/vol) glycerol, deglycerolized in the ACP 215, and stored at 4 degrees C in AS-3 for up to 21 days.

BACKGROUND: The FDA has approved the storage of frozen RBCs at -80 degrees C for 10 years and the postwash storage at 4 degrees C for no more than 24 hours. The 4 degrees C postwash storage period is limited to 24 hours, because the current deglycerolization systems are functionally open systems. STUDY DESIGN AND METHODS: Two units of RBCs were collected from each of 13 healthy male volunteers. The RBCs were collected in CP2D by the FDA-approved protocol for an automated apheresis device (MCS, LN8150, Haemonetics) and were stored at 4 degrees C in AS-3 for 6 days. Using a single disposable glycerolization set in an automated, functionally closed system (ACP 215, Haemonetics) each unit was transferred to a 1000-mL PVC plastic bag and glycerolized to a concentration of 40-percent (wt/vol) glycerol and frozen at -80 degrees C. A single disposable deglycerolization set in the ACP 215 was used to deglycerolize the 2 units from the same donor. The deglycerolized RBCs were stored at 4 degrees C in AS-3 for as long as 21 days. RESULTS: The mean +/- SD freeze-thaw-wash recovery value was 89.4 +/- 3 percent. The residual hemolysis in the RBCs stored at 4 degrees C in AS-3 for 21 days after deglycerolization was 0.9 +/- 0.2 percent, and the units were negative for both aerobic and anaerobic bacteria. The mean Nageotte WBC count was 9 x 10(6) per unit. When the deglycerolized RBCs were given as an autologous transfusion after storage at 4 degrees C in AS-3 for the 7- to 18-day period, the mean +/- SD 24-hour posttransfusion survival was 77 +/- 7 percent, and the index of therapeutic effectiveness was 69 +/- 8 percent. CONCLUSION: Two units of human RBCs collected from a single donor by apheresis in the MCS using an LN8150 set can be glycerolized sequentially with a single disposable set and deglycerolized sequentially with another single disposable set in the ACP 215. The previously frozen RBCs stored in AS-3 for 7 to 18 days at 4 degrees C had acceptable hemolysis and an acceptable mean 24-hour posttransfusion survival value and index of therapeutic effectiveness.

Adenine↗

The role of airway secretions in COPD--clinical applications.

It has been established that mucus hypersecretion and decreased mucus clearance contribute to the morbidity of chronic obstructive pulmonary disease (COPD). Indeed, the classic definition of chronic bronchitis relies on determining the frequency and duration of sputum expectoration. Despite the well recognized importance of this symptom, there are few therapies routinely used to decrease the sputum production or to improve clearance. There are fewer well conducted clinical trials of existing medications and this has led many regulatory agencies, notably the Food and Drug Administration (FDA), to refuse to register these medications or approve their sale. Similarly, airway clearance devices and chest physical therapy have not been well studied in COPD. Carefully conducted studies of interventions to improve airway clearance, similar to those done in cystic fibrosis (CF), may help us to identify effective therapies and possibly novel diagnostic tests for the management of COPD.

Expectorants↗

Planning for effective interaction with FDA.

Manufacturers of diabetes devices can facilitate the formal regulatory approval process through early interaction with the U.S. Food and Drug Administration (FDA). Effective planning can help manage commonly perceived risks of interaction with the Agency, introduce new technologies to regulatory reviewers, and inform the manufacturer's product development strategy. This article reviews key aspects of the FDA evaluation process and suggests strategies that may facilitate effective communication with the Agency. Integrating early communication with FDA into broader product commercialization planning can streamline regulatory review and lead to early product launch into reimbursed markets.

Aged↗

Clinical trial: a clinician's perspective.

As a result of my participation in several clinical trials at The University of Iowa, I have now redrawn what I perceive to be the algorithm for conduct of a clinical trial. Of note, I have excluded the development of the new device, in vitro device testing, in vivo animal experimentation, clinical protocol development, granting of an Investigational Device Exemption, and the process by which clinical sites are selected. Following my algorithm I have made no mention of the commercialization of an experimental device, including the Pre-Market Approval process and FDA panel meetings. In summary, I believe there are a variety of reasons why a principal investigator would choose to participate in a clinical trial. With tongue in cheek, I would offer fame and fortune as two possible motivating factors. Obviously, both are double-edged swords. Should a trial not turn out as hoped, celebrity can instantly turn to notoriety. With respect to fortune, administrative and clinical activity performed by the principal investigator on behalf of the clinical trial does not generate income, and, in fact, can place a considerable financial drain on the investigator's department. I believe that investigators are strongly driven by intellectual curiosity, but it is important to maintain perspective when participating in a clinical trial. The real reason we seek clinical trial site designation is to allow us to offer new, innovative therapeutic modalities to our patients. By so doing, it is imperative that we conduct the clinical trial in as thoughtful and as safe a manner as possible, with our patients' well being always foremost in our minds.

Clinical Trials as Topic↗

Evaluation of clinical effectiveness of MIST ultrasound therapy for the healing of chronic wounds.

OBJECTIVES: (1) To determine the incidence of wound closure for chronic nonhealing lower extremity wounds of various etiologies using MIST ultrasound therapy, a 510(K)-approved, low-frequency, noncontact ultrasound device indicated for the cleansing and debridement of chronic wounds. (2) To determine the optimum treatment duration for therapy with this low-frequency, noncontact ultrasound device, quantifying end points that correlate with a maximal clinical response and identifying potential synergistic therapies that could be used in conjunction with this therapy. (3) To analyze the impact of low-frequency noncontact ultrasound therapy on the microcirculatory flow patterns within the wound bed. DESIGN: A noncomparative clinical outcomes trial utilizing low-frequency, noncontact ultrasound. SETTING: A tertiary-referral hospital-based wound clinic. PATIENTS: Twenty-three patients from a single tertiary-referral hospital-based wound clinic. Control data were obtained from a previously published, prospectively collected database from the same clinic. INTERVENTIONS: During an 8-month period, a total of 29 lower extremity wounds in 23 patients who met criteria for inclusion were treated with low-frequency, noncontact ultrasound therapy. Standard of care was provided for 2 weeks for all wounds screened for the study. A failure to achieve an area reduction greater than 15% qualified the patient for enrollment to the trial and the addition of low-frequency, noncontact ultrasound therapy to the current treatment regimen. MAIN OUTCOME MEASURES: Wound healing, area and volume reduction, and laser Doppler-derived mean voltage (a marker for microcirculatory flow) are the main outcome measures for the study. RESULTS: Overall, 69% of the wounds in the study were healed using an intent-to-treat model. When low-frequency, noncontact ultrasound was used as a stand-alone device, median time to healing was 7 weeks. Historic controls were healed with a median time to healing of 10 weeks; however, a statistically significant number of these patients required wound-related hospitalization and surgical procedures to achieve closure compared with the wounds in the present study. CONCLUSIONS: Treatment with low-frequency, noncontact ultrasound achieved healing in chronic wounds when used as a stand-alone device or in combination with moist wound care in 69% of cases. Response to low-frequency, noncontact ultrasound was evident within 4 weeks of therapy. Earlier transition to secondary procedures and decreased utilization of inpatient care might result in more cost-effective wound healing than the current standard of care. A well-designed health economic-based trial is warranted to assess this technology.

Aged↗

United States' trends and regional variations in lumbar spine surgery: 1992-2003.

STUDY DESIGN: Repeated cross-sectional analysis using national Medicare data from the Dartmouth Atlas Project. OBJECTIVE: To describe recent trends and geographic variation in population-based rates of lumbar fusion spine surgery. SUMMARY OF BACKGROUND DATA: Lumbar fusion rates have increased dramatically during the 1980s and even more so in the 1990s. The most rapid increase appeared to follow the approval of a new surgical implant device. METHODS: Medicare claims and enrollment data were used to calculate age, sex, and race-adjusted rates of lumbar laminectomy/discectomy and lumbar fusion for fee-for-service Medicare beneficiaries over age 65 in each of the 306 US Hospital Referral Regions between 1992 and 2003. RESULTS: Lumbar fusion rates have increased steadily since 1992 (0.3 per 1000 enrollees in 1992 to 1.1 per 1000 enrollees in 2003). Regional rates of lumbar discectomy, laminectomy, and fusion in 1992-1993 were highly correlated to rates of discectomy, laminectomy (R2 = 0.44), and fusion (R2 = 0.28) in 2002-2003. There was a nearly 8-fold variation in regional rates of lumbar discectomy and laminectomy in 2002 and 2003. In the case of lumbar fusion, there was nearly a 20-fold range in rates among Medicare enrollees in 2002 and 2003. This represents the largest coefficient of variation seen with any surgical procedure. Medicare spending for inpatient back surgery more than doubled over the decade. Spending for lumbar fusion increased more than 500%, from 75 million dollars to 482 million dollars. In 1992, lumbar fusion represented 14% of total spending for back surgery; by 2003, lumbar fusion accounted for 47% of spending. CONCLUSIONS: The rate of specific procedures within a region or "surgical signature" is remarkably stable over time. However, there has been a marked increase in rates of fusion, and a coincident shift and increase in cost. Rates of back surgery were not correlated with the per-capita supply of orthopedic and neurosurgeons.

Aged↗

Current clinical issues for MRI scanning of pacemaker and defibrillator patients.

Dramatic increases in both magnetic resonance imaging (MRI) usage and cardiac device-based therapy have resulted in an estimated 50-75% probability of a patient being indicated for an MRI over the lifetime of their device. Some recent studies have demonstrated "safe procedures" and "no adverse events" in the limited populations, clinical situations, and specific devices and lead orientations tested. While these investigations are useful to help ascertain the hazards for patients with cardiac devices, they do not demonstrate clear freedom from risk. All components of active implantable systems must be engineered during the design stage to provide safety in current and evolving MR environments. Device manufacturers need to secure regulatory approval to confirm their products' safety under multiple clinical and technical variables.

Defibrillators, Implantable↗

Robots in operating theatres.

Robots designed for surgery have three main advantages over humans. They have greater three dimensional spatial accuracy, are more reliable, and can achieve much greater precision. Although few surgical robots are yet in clinical trials one or two have advanced to the stage of seeking approval from the UK's Medical Devices Agency and the US Federal Drug Administration. Safety is a key concern. A robotic device can be designed in an intrinsically safe way by restricting its range of movement to an area where it can do no damage. Furthermore, safety can be increased by making it passive, guided at all times by a surgeon. Nevertheless, some of the most promising developments may come from robots that are active (monitored rather than controlled by the surgeon) and not limited to intrinsically safe motion.

Humans↗

The bionic ear: principles and current status of cochlear prostheses.

The field of cochlear prostheses is reviewed, emphasizing the neurophysiological principles necessary for the development of a successful cochlear prosthesis. Pertinent auditory physiology is reviewed, and four conditions are proposed which, if met, should result in speech recognition by the patient with an implant. These conditions are: The surviving neural population must be adequate over the frequency distribution required to deliver the necessary information for speech discrimination. The central neural processing pattern for decoding and recognizing speech must have been established and still persist. The processing of the acoustic signal by the auditory system up to the level of the prosthesis interface must be understood and predictable from the acoustic stimulus. The relationship between the response patterns of the neural elements and the electrical stimulus must be well documented and controllable. The degree to which these conditions can presently be met is discussed, with some suggestions for future development. The function of the cochlear prosthesis is separated into a signal processing section and an electrical stimulus section. Two signal processing strategies are analog processing of the acoustic signal and speech feature extraction from the acoustic signal. Four possible electrical stimulation strategies are direct analog stimulation from the signal processor, pulse amplitude modulation, pulse width modulation, and stimulation designed to optimize the neural responses to electrical stimulation. Some of the present generation cochlear prostheses, including five approved by the FDA as investigational devices, are discussed according to this classification. The clinical results of testing these devices as aids to lip reading and as stand-alone speech reception aids are compared. All are a potential aid to lip reading. Some prosthesis designs have been implanted in patients who then showed exceptional open set speech discrimination. These exceptional patients have used both single channel and multichannel devices and devices with both analog processing and speech feature extraction strategies. These results are encouraging. More consistent and better speech reception is anticipated for the future as this field develops.

Auditory Pathways↗

Development of a prosthetic coronary artery bypass graft.

BACKGROUND: The patient population undergoing repeat coronary revascularization is increasing, with estimates of approximately 15% of these patients in need of alternative conduits. Pre-existing conditions may limit the availability of suitable autogenous vessels for complete coronary revascularization. As an alternative, previous investigators have attempted to develop prosthetic conduits for coronary artery bypass grafting (CABG), but as yet without clinical success. To be of clinical benefit, a prosthetic graft would require demonstrated patency at least as good as a marginal quality autogenous vessel used in the same position, without unexpected adverse effects. The use of a prosthetic graft may also reduce surgical complications associated with conduit harvesting and thereby enhance the speed of patient recovery. METHODS: Our group has investigated the potential of a novel synthetic small diameter vascular graft (2.5- to 3.5-mm diameter), as an alternative conduit for CABG. The graft is designed with three distinct layers composed of Thoralon, a proprietary polyetherurethaneurea with a silicone-based surface modifying additive. This biomaterial is the same material successfully used for the thromboresistant blood-contacting surfaces of an FDA approved and clinically successful ventricular assist device. RESULTS: Aria grafts underwent extensive preclinical testing in sheep with results to over one year that demonstrate the graft's biocompatibility, biodurability, and ability to maintain patency in both peripheral access graft and coronary applications. Compassionate use human coronary implants have been performed in 27 patients in the coronary position in Canada and Europe. Although incomplete, the data demonstrate no device related serious injury or and all surviving patients have remained symptom free. CONCLUSIONS: A prosthetic coronary artery bypass graft has been developed and has undergone extensive pre-clinical testing and preliminary clinical use. Based upon the results, a prospective, randomized, controlled clinical study, the AEGIS/Canada (AlternativE Graft Investigational Study) trial using the Aria graft in the coronary position in human patients is underway. Additionally, a pre-IDE submission has been submitted to the FDA to expand the AEGIS clinical trial device to the United States.

Animals↗

Allergic reactions to natural rubber.

Immediate hypersensitivity reactions to natural rubber pose a significant risk to patients with spina bifida and urogenital abnormalities, health care workers, and rubber industry workers. Other patients, outside of these high risk groups, have experienced severe allergic reactions to natural rubber as well. Awareness of this life-threatening condition by health care providers is essential if reactions are to be prevented. History alone is inadequate to identify all patients at risk, and reliable testing materials are not yet approved or widely available. Nonrubber medical devices are readily available for most uses; however, the only rubber-free condoms currently on the market do not prevent the transmission of sexually transmitted disease. The identification and detection of rubber antigens, along with mandated labeling for rubber antigen content, will contribute to the care of this growing population of patients. Efforts by the rubber industry to decrease the antigen content of natural rubber products will decrease the risk of reaction among sensitized patients and will, very likely, decrease the rate of sensitization in the future.

Humans↗

The LifeShirt: a multi-function ambulatory system monitoring health, disease, and medical intervention in the real world.

Despite advances made in health-related ambulatory monitoring, medical practitioners and researchers have remained seriously constrained in their ability to acquire concurrent assessments of multiple physiological systems, as well as patient reports of symptoms and well being in daily life: Almost all past and current applications have been limited to the registration of a single variable (e.g. the electrocardiogram or blood pressure), and this has resulted in incomplete information about other relevant physiological and environmental factors likely to contribute to disease or its amelioration. Monitoring of multiple physiological functions has been too complicated to achieve and has required special measurement devices that have been unavailable, too expensive, or too cumbersome to effectively employ. Concurrent assessment of pertinent information about patient activities during monitoring has remained difficult to accomplish, although such information is likely to be crucial for the interpretation of physiological findings and patients' perceptions of improvement. The LifeShirt (Vivometrics, Inc., Ventura, CA, U.S.A.) is a multi-function ambulatory device capable of simultaneously monitoring several physiological signals and patient reports of symptoms and well being. The LifeShirt system is an extensible data acquisition and processing platform consisting of a garment, a data recorder, and PC-based analysis software. Sensors in the LifeShirt garment continuously monitor respiration, the electrocardiogram, activity and posture. Other functions are easily plugged into the system, including pulse oximetry, EEG/ EOG measurement, blood pressure, temperature, capnometry and acoustic monitoring. Subjective patient data may also be entered into the LifeShirt recorder, and all data are encrypted and written to a flash memory card. Vivologic(TM) analysis software provides full-disclosure analysis and display of high-resolution waveforms and over 30 derived parameters; the software also produces summary reports for clinical diagnostic purposes. The LifeShirt has been rigorously tested for more than 38,000 hours in 90 studies with 1,750 subjects. The device has received all necessary regulatory approvals and is currently used in leading research institutions throughout the United States, Canada and Europe. Clinical applications include sleep diagnostics, heart disease, pulmonary disorders, cardiopulmonary rehabilitation, early hospital discharge and pre- and post-operative monitoring, human-factors in ergonomics and behavioral medicine.

Cardiovascular Diseases↗

Declassifying coverage. New guidance documents issued by the CMS may clarify the great unknown of Medicare coverage determination.

Heard of Section 731 of the Medicare Modernization Act? The provision, meant to clear up the generally murky and unwieldy Medicare reimbursement approval process, could quicken the national approval process for medical procedures and devices. The changes will create a more definable approach to OK'ing new technologies. "I like the idea of bringing more science to bear," says Richard Pico, left.

Aged↗

Experiences with an artificial sphincter to establish anal continence in dogs.

An implantable device for establishing urinary continence has been developed and has received FDA approval (AS 800, American Medical Systems, Inc.). The authors have applied this device to the control of anal continence in dogs. Fifteen mongrel dogs underwent either anal sphincter disruption (7) or abdominal-perineal resection (8). Such animals have bowel movements almost hourly. In each case, the device was implanted at the time of surgery. In dogs with working cuffs and disabled or absent sphincters, continence was maintained in seven out of 15 animals for periods of 4-8 hours. After cuff activation, intraluminal cuff pressures of 50-70 cm of water achieved continence for a period of 8 hours. In animals sacrificed from 1 to 12 months after implantation, the device was found to be well tolerated by the body with minimal fibrosis of the mucosa or muscularis of the bowel. Complications observed in the same four out of 15 animals during the study period were infection, device extrusion, and device malfunction. Infection resolved with local wound care and antibiotics (3/4) and the device was successfully replaced in two out of four instances of extrusion. With cuffs of proper size and pressure, this appliance may be effective in the control of human anal incontinence via the establishment of continent perineal colostomies following an abdominal-perineal resection.

Animals↗

Laser angioplasty: historical perspective.

Serious interest in laser angioplasty began in the early 1980s in an attempt to solve two of the primary limitations of balloon angioplasty, recanalization and restenosis. By demonstrating the ability of laser irradiation to vaporize atherosclerotic tissue, it was logical to hypothesize that this powerful tool may allow recanalization of lesions that could not be crossed by conventional guidewire and balloon technology. With refinements in laser fibreoptics and catheter delivery systems, several laser systems were approved for clinical use as recanalization devices in both peripheral and coronary arteries. However, the requirement to follow laser angioplasty with conventional balloon angioplasty in the majority of cases and the lack of an effect of laser tissue removal (debulking) on restenosis has limited a broader acceptance of this technology. Perhaps improved techniques discussed later in this series such as saline infusion and better fibreoptic-lens systems will allow laser angioplasty to offer a true niche in interventional cardiology.

Angioplasty, Laser↗

Medical Device Amendments of 1976.

The Medical Device Amendments of 1976 are discussed with particular reference to the history of device regulation, classification of devices, performance standards, applications for premarket approval and testing protocols.

Legislation, Medical↗

The left ventricular assist device (LVAD). A bridge to heart transplantation.

Since its approval by the USFDA in 1998, the LVAD has been used primarily as a bridge to transplantation. It has been effective in improving the overall health and debilitated states in patients with cardiomyopathies and CHF by restoring them to a near normal hemodynamic state and improving end-organ blood flow. Recent studies indicate that the LVAD might be useful as a destination therapy, making transplantation unnecessary, providing one solution to the imbalance of heart donor supply to transplant candidate need.

Contraindications↗

Gastroparesis and the gastric pacemaker: a revolutionary treatment for an old disease.

Gastroparesis--or delayed gastric emptying--can apply to either solids or liquids but the term (gastroparesis) usually refers to delayed solid emptying, in an appropriate clinical setting. Impaired gastric emptying can occur acutely in a variety of conditions from neurologic to metabolic. Intractable nausea and vomiting, and the inability to tolerate oral intake, occurs frequently in patients with severe gastroparesis. The patients' nutritional status is adversely affected by gastroparesis as are the socioeconomic aspects of patient's lives. The previous treatments of gastroparesis, such as medications and surgery, were often not successful. Our recent understanding of the normal gastric electro-mechanical function and its abnormalities/dysrythmias has led to the development of a gastric electrical stimulator, analagous to other devices used to stimulate dysfunctional organs. Gastric electrical stimulation is associated with improvements in symptomatic relief, nutritional status, health resource utilization and costs and is now approved by the FDA as a humanitarian use device. It offers a new and hopeful therapy for patients with refractory gastroparesis where none have existed before.

Electric Stimulation Therapy↗